The relevant information included in this section is exactly as published on the website of the National Securities Market Commission (CNMV)
Filter results
| Date | Title | |
|---|---|---|
| 20/10/2021 | The FDA delays its decision on Risperidone ISM® | |
| 1/09/2021 | ROVI informs about the joint statement from Moderna and Takeda on the investigation of suspended lots of the vaccine | |
| 29/08/2021 | ROVI informs on the evolution of the investigation of particulate matter having been seen in certain drug product vials of the Moderna COVID-19 vaccine distributed in Japan | |
| 26/08/2021 | ROVI informs on the notification of particulate matter having been seen in certain drug product vials of the Moderna's COVID-19 vaccine distributed in Japan | |
| 9/08/2021 | ROVI achieves second place in a worldwide sustainability rating | |
| 28/07/2021 | First half 2021 results press release | |
| 13/05/2021 | First quarter 2021 results press release | |
| 29/04/2021 | ROVI increases its fill-finish capacity for the COVID-19 Vaccine Moderna | |
| 12/04/2021 | ROVI participates in the manufacture of the active substance of Moderna’s COVID-19 vaccine | |
| 2/03/2021 | Update on Doria® regulatory processes |